GlaxoSmithKline received approval from the FDA for Promacta (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic ITP.      Chronic ITP is a bleeding disorder marked by increased platelet destruction and/or inad...